Romina Sepe1, Salvatore Piscuoglio2, Cristina Quintavalle3, Valeria Perrina3, Luca Quagliata3, Umberto Formisano1, Luigi Maria Terracciano3, Alfredo Fusco4, Pierlorenzo Pallante1. 1. Istituto per l'Endocrinologia e l'Oncologia Sperimentale (IEOS) "G. Salvatore", Consiglio Nazionale delle Ricerche (CNR), Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), Università degli Studi di Napoli "Federico II", Naples, Italy. 2. Molecular Pathology Division, Institute of Pathology, University of Basel, Basel, Switzerland Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Molecular Pathology Division, Institute of Pathology, University of Basel, Basel, Switzerland. 4. Istituto per l'Endocrinologia e l'Oncologia Sperimentale (IEOS) "G. Salvatore", Consiglio Nazionale delle Ricerche (CNR), Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), Università degli Studi di Napoli "Federico II", Naples, Italy Instituto Nacional de Câncer-INCA, Rua André Cavalcanti, 37-Centro, Rio de Janeiro, Brazil.
Abstract
OBJECTIVES: Breast cancer represents the second leading cause of cancer mortality among American women and accounts for more than 40 000 deaths annually. High-mobility group A1 (HMGA1) expression has been implicated in the pathogenesis and progression of human malignant tumours, including breast carcinomas. The aim of this study was to evaluate HMGA1 detection as an indicator for the diagnosis and prognosis of human breast carcinoma. METHODS: HMGA1 expression has been analysed by immunohistochemistry in a large series of breast carcinoma resections (1338) combined on a tissue microarray mainly including the ductal carcinoma variant. The results were then correlated with clinicopathological parameters of patients. RESULTS: HMGA1 overexpression was found in the large majority of breast carcinoma samples and its overexpression positively correlated with HER-2/neu amplification and progesterone receptor, while a negative correlation was found with oestrogen receptor. Conversely, no HMGA1 expression was found in normal breast tissues. CONCLUSIONS: The data reported here indicate that HMGA1 is overexpressed in human breast carcinomas and its levels are associated with a particular endocrine status. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES:Breast cancer represents the second leading cause of cancer mortality among American women and accounts for more than 40 000 deaths annually. High-mobility group A1 (HMGA1) expression has been implicated in the pathogenesis and progression of humanmalignant tumours, including breast carcinomas. The aim of this study was to evaluate HMGA1 detection as an indicator for the diagnosis and prognosis of humanbreast carcinoma. METHODS:HMGA1 expression has been analysed by immunohistochemistry in a large series of breast carcinoma resections (1338) combined on a tissue microarray mainly including the ductal carcinoma variant. The results were then correlated with clinicopathological parameters of patients. RESULTS:HMGA1 overexpression was found in the large majority of breast carcinoma samples and its overexpression positively correlated with HER-2/neu amplification and progesterone receptor, while a negative correlation was found with oestrogen receptor. Conversely, no HMGA1 expression was found in normal breast tissues. CONCLUSIONS: The data reported here indicate that HMGA1 is overexpressed in humanbreast carcinomas and its levels are associated with a particular endocrine status. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
BREAST CANCER; CARCINOMA; IMMUNOHISTOCHEMISTRY
Authors: Mariacarla Andreozzi; Cristina Quintavalle; David Benz; Luca Quagliata; Matthias Matter; Diego Calabrese; Nadia Tosti; Christian Ruiz; Francesca Trapani; Luigi Tornillo; Alfredo Fusco; Markus H Heim; Charlotte Ky Ng; Pierlorenzo Pallante; Luigi M Terracciano; Salvatore Piscuoglio Journal: Neoplasia Date: 2016-11-14 Impact factor: 5.715
Authors: Olga Méndez; José Pérez; Jesus Soberino; Fabricio Racca; Javier Cortés; Josep Villanueva Journal: Int J Mol Sci Date: 2019-11-26 Impact factor: 5.923